Drew M. Pardoll, M.D., Ph.D.

Johns Hopkins University School of Medicine
Baltimore, MD

Dr. Drew M. Pardoll is the director of the Bloomberg-Kimmel Cancer Institute for Cancer Immunotherapy, the director of the Division of Immunology, and the Abeloff Professor at the Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University School of Medicine.

Dr. Pardoll discovered γΔ (gamma-delta) T cells, natural killer T (NKT) cells, and interferon-producing killer dendritic cells (IKDCs), and helped develop two cancer vaccine approaches. Perhaps most importantly, he discovered a protein that binds to the PD-1 immune checkpoint receptor, which contributed to the development of anti-PD-1 checkpoint inhibitor immunotherapies. He has been elected to the Association of American Physicians, and continues to explore the most effective immunotherapy strategies with the aim of getting them into the clinic to help patients.

In addition to being a member of CRI’s Scientific Advisory Council, Dr. Pardoll serves on the Postdoctoral Fellowship Review Committee, is a leader of the CRI-SU2C Dream Team, and is a member of CRI’s global clinical investigator network.

{In 1984] I decided two things. One was that the immune system was the most powerful anticancer weapon that we had, more powerful than any drug. The other was that we had to understand how to regulate it so we could focus it more on the cancer.
Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.